Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cervical Cancer clinical trials
73 of 151 indexed Cervical Cancer trials are currently recruiting.
151 US clinical trials · 73 currently recruiting
Cervical Cancer is the subject of 151 registered US clinical trials on ClinicalTrials.gov, 73 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 78 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 11 of these trials.
The research picture
Cervical Cancer has 151 registered US clinical trials, 73 of them open to new participants right now, about 48% of the total.
- 73
- recruiting participants now
- 48%
- of trials open to enrollment
- 8
- in Phase 3–4 (later-stage)
- 11
- top sponsor: M.D. Anderson Cancer Center
Active & Recent Trials
151 total, page 1 of 4
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
M.D. Anderson Cancer Center
NCT05359016
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Adela
NCT05366881
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Northwestern University
NCT00005095
Novel, One Stop, Affordable, Point of Care and AI Supported System of Screening, Triage and Treatment Selection for Cervical Cancer in LMICs
International Agency for Research on Cancer
NCT06042543
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Mayo Clinic
NCT05051722
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
University of California, San Diego
NCT06128304
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics
NCT04510129
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Merck Sharp & Dohme
NCT07216703
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04895709
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
GOG Foundation
NCT04831580
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT06172478
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Merck Sharp & Dohme
NCT06459180
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
Abramson Cancer Center at Penn Medicine
NCT05952141
Rice Technologies for Cervical Cancer Screening and Diagnosis
M.D. Anderson Cancer Center
NCT05372484
Reducing Urban Cervical Cancer Disparities
Fox Chase Cancer Center
NCT06416150
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT06238479
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Diwakar Davar
NCT07223424
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech
NCT05581004
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
NCT06465069
Cervical Cancer Detection Using Optical Spectroscopy
Duke University
NCT00900575
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
NCT04916990
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
GI Innovation
NCT04977453
Pilot Study for Speculum Free Cervical Cancer Screening
Duke University
NCT04107181
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune
NCT06293898
Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama
University of Alabama at Birmingham
NCT04093388
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences
NCT07109726
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma
NCT07227168
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
Northwestern University
NCT05743517
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Normunity AccelCo
NCT07182149
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies
NCT06047379
Study of NEO-201 in Solid Tumors Expansion Cohorts
Precision Biologics
NCT03476681
PopSci CHW4CervixHealth
Thomas Jefferson University
NCT07336134
Mindfulness in Endometrial and Cervical Cancer
St. Louis University
NCT04512144
A Beta-only IL-2 ImmunoTherapY Study
Medicenna Therapeutics
NCT05086692
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT06239194
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
AstraZeneca
NCT06535607
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
NCT06973161
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Pfizer
NCT06952660
Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers
Northwell Health
NCT05606133
DESTINY-PANTUMOUR04
AstraZeneca
NCT07124000
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
NCT06999187
ASk Questions in GYnecologic Oncology (ASQ-GYO)
Ira Winer
NCT06339827
Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)
Medtronic - MITG
NCT07120945
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
University of Utah
NCT05979610
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
University of California, Irvine
NCT07064018
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Radiopharm Theranostics
NCT07189871
Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers
Jonsson Comprehensive Cancer Center
NCT06538337
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
Washington University School of Medicine
NCT05975593
A Study of VET3-TGI in Patients With Solid Tumors
KaliVir Immunotherapeutics
NCT06444815
Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy
University of Florida
NCT07214584
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 30 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Cervical Cancer Trial Landscape
151 indexed Cervical Cancer studies · 73 recruiting (48%).
Phase mix: 8 late (III/IV) vs 78 early (I/II).
Top sponsor: M.D. Anderson Cancer Center (11 trials), 9 others listed. 50 shown below, recruiting first.
How to read this condition's trial landscape
That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Cervical Cancer?
PlainTrial tracks 151 US clinical trials for Cervical Cancer, of which 73 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Cervical Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.